The Radiant Creations Group, Inc. (RCGP) (f.k.a. Nova Mining Corporation) was incorporated in the state of Nevada in 2005 as an exploration stage company in the business of acquisition and exploration of mineral resources.
In June 2013, control of the company was acquired by the founders’ of The Radiant Creations Group under the name BioDynamic Molecular Technologies. Immediately following the change in control, the company acquired the assets and certain liabilities of Renewable BioScience Technologies.
The company is authorized to issue an aggregate of 200,000,000 shares of capital stock including 100,000,000 common shares and 100,000,000 preferred shares. Following the closing of the asset acquisition, the company had approximately 44,125,000 common shares outstanding and no preferred shares issued.
The company intends to increase its capital structure to approximately 65,000,000 common shares outstanding through the issuance of restricted shares to accredited investors by private subscription agreement, pricing to reflect approximately 50% of the current trading prices of common shares. Proceeds from the capital raise to be used to acquire additional inventory and initiate production of Revivasol’s Acne Gone product.
The Radiant Creations Group, Inc. common stock trades on the over-the-counter market (OTC: BB) under the symbol RCGP.
As with all business venture, the development of new and innovative products has significant risks and uncertainties, even with advanced patented, patent-pending and proprietary technologies and methods, such as Radiant Creations. Some of these risks are discussed below, and Radiant believes these risks are some of the most significant concerns. Nevertheless, this list is not exhaustive and other issues need traditional discussion and reviews.
There is a risk that Radiant Creations’ products could fail to meet regulatory requirements. Despite the advanced techniques and previous significant success of similar products, various complications could cause a selected product to fail certain regulatory requirements. If the selected product failed, additional monies would be needed to test other products. Such other products could also fail regulatory requirements.
There is a risk that Radiant Creations’ products, even after completing an initial marketing study, could be difficult to sell, or might not be purchased in volumes sufficient to achieve profitability. Market risks for new skin care and health care products has increased over the past decade. Tight capital markets and reduced R&D budgets have forced companies to pursue lower risk and later stage licensing methods. Companies typically wait until the product has been shown to be marketable before pursuing an acquisition. On the upside, new OTC candidates at this stage can reach values far in excess of anticipated or protection results.
Radiant faces technical and market risks. Risks of either kind could cause any investment in the company to be a material, and potentially complete loss.